College of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
Structure. 2024 Sep 5;32(9):1301-1321. doi: 10.1016/j.str.2024.08.005.
The coronavirus disease 2019 (COVID-19), the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents the most disastrous infectious disease pandemic of the past century. As a member of the Betacoronavirus genus, the SARS-CoV-2 genome encodes a total of 29 proteins. The spike protein, RNA-dependent RNA polymerase, and proteases play crucial roles in the virus replication process and are promising targets for drug development. In recent years, structural studies of these viral proteins and of their complexes with antibodies and inhibitors have provided valuable insights into their functions and laid a solid foundation for drug development. In this review, we summarize the structural features of these proteins and discuss recent progress in research regarding therapeutic development, highlighting mechanistically representative molecules and those that have already been approved or are under clinical investigation.
2019 年冠状病毒病（COVID-19），由严重急性呼吸系统综合征冠状病毒 2 型（SARS-CoV-2）引起的疾病，代表了过去一个世纪最具灾难性的传染病大流行。作为贝塔冠状病毒属的一员，SARS-CoV-2 基因组总共编码 29 种蛋白质。刺突蛋白、RNA 依赖性 RNA 聚合酶和蛋白酶在病毒复制过程中发挥着关键作用，是药物开发的有前途的靶点。近年来，这些病毒蛋白及其与抗体和抑制剂复合物的结构研究为它们的功能提供了有价值的见解，并为药物开发奠定了坚实的基础。在这篇综述中，我们总结了这些蛋白质的结构特征，并讨论了治疗开发的最新进展，重点介绍了具有代表性的分子机制和已批准或正在临床研究的分子。
